AmerisourceBergen (ABC) venture capital fund to help healthcare


AmerisourceBergen Corporation ABC recently launched AB Health Ventures – a dedicated enterprise venture capital fund – focused on investing in and collaborating with emerging healthcare startups involved in transforming healthcare for people and animals in the whole world. This venture capital fund will build on AmerisourceBergen’s ongoing commitment to delivering innovation to its customers.

It should be mentioned that AB Health Ventures is a wholly owned subsidiary of AmerisourceBergen which will utilize the company’s depth of expertise, global presence and strong relationships with stakeholders across the supply chain. pharmaceutical supply to increase the value of entrepreneurs who are looking for partners to help business growth.

Through the creation of a dedicated venture capital fund, AmerisourceBergen can help startups accelerate solution prototypes, test with pilots, and scale through commercialization.

Importance of AB Health Ventures

According to management, the introduction of AB Health Ventures can help unlock new ideas, add value and provide potential solutions that can benefit its customers and the patients they serve.

Image source: Zacks Investment Research

Over a significant period of time, AmerisourceBergen has made thoughtful and strategic investments to accelerate healthcare development and delivery, enable access, and create more stability throughout the supply chain. The creation of AB Health Ventures can help build on the company’s track record of success (the company collaborated with TrakCel as well as Annexus Health in January) through the identification of substantial partnerships, which can provide healthcare emerging in the marketplace and building a healthier future for all.

Initially, AB Health Ventures will launch with $150 million allocated to invest in early-stage to mid-stage health-related startups globally. The fund will prioritize investments in entrepreneurs who are pursuing different ideas in areas such as the future of pharmacy and distribution, clinical development and commercialization of pharmaceuticals, to name a few.


This month, AmerisourceBergen’s national network of independent community pharmacies – Good Neighbor Pharmacy – announced that it had exceeded five million doses of COVID-19 vaccine allocated to independent pharmacies across the United States. This allocation effort is part of the Federal Retail Pharmacy Program for COVID-19 Immunization, which is a partnership between the federal government, U.S. states and territories, and 21 national pharmaceutical partners, including Good Neighbor Pharmacy.

In February, the company added TRIOSE’s freight management capabilities to its portfolio of business solutions that can help AmerisourceBergen customers better manage their supply chain operations, gain cost visibility and realize more savings.

Price performance

Shares of Zacks Rank #3 (Hold) gained 40.8% year-on-year, versus 9.8% for the sector.

Actions to consider

Some higher ranked stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. AMN, Edwards Life Sciences Society and Henry Schein, Inc. HSIC.

AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings have exceeded estimates in each of the past four quarters, with the average surprise being 20%. It currently sports a Zacks rank #1 (Strong Buy). You can see the full list of today’s Zacks #1 Rank stocks here.

AMN Healthcare gained 36.7% against a 55.2% decline in the sector over the past year.

Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13.9%. EW’s earnings beat estimates in three of the past four quarters and missed once, with the average surprise coming in at 6.5%.

Edwards Lifesciences rose 44.4% compared to the sector’s 0.9% rise over the past year.

Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings have exceeded estimates in each of the past four quarters, with the average surprise being 25.5%. He currently has a No. 2 Zacks rank.

Henry Schein jumped 29.1% from the industry rally of 9.8% over the past year.

5 shares ready to double

Each was handpicked by a Zacks expert as the #1 preferred stock to earn +100% or more in 2021. Previous recommendations have skyrocketed +143.0%, +175.9%, + 498.3% and +673.0%.

Most of the stocks in this report fly under the radar on Wall Street, which provides a great opportunity to get in on the ground floor.

Today, check out these 5 potential home runs >>

Click to get this free report

AmerisourceBergen Corporation (ABC): Free Inventory Analysis Report

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Henry Schein, Inc. (HSIC): Free Stock Analysis Report

AMN Healthcare Services Inc (AMN): Free Inventory Analysis Report

To read this article on, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


About Author

Comments are closed.